ABVX
Abivax S.A.
NASDAQ · Healthcare · Biotechnology · FR
$114.01
−0.02%Forward multiples
Based on analyst estimates
- P/E forward
- —
- P/E 2026E
- —
- P/E 2027E
- —
- P/E 2028E
- 243.42x
- P/S forward
- 2068.56x
Trailing multiples
Trailing twelve months
- P/E TTM
- —
- PEG TTM
- —
- Price / book
- 18.81x
- Price / sales
- —
- Price / cash flow
- -45.44x
Enterprise value
- Enterprise value
- $9.4B
- EV / sales
- —
- EV / EBITDA
- -21.09x
- EV / EBIT
- -24.57x
- Market cap
- $9.9B
Trailing, forward and enterprise-value multiples for the requested listing · Data as of Dec 1, 2025